Toronto's
Segasist Technologies, whose founder, Dr. Hamid Tizhoosh, told Yonge Street
in September that he expected US Food and Drug Administration approval for his oncology diagnostic product this fall, recently received that approval.
"For a small company such as ours, this is amazing," Tizhoosh says. "FDA approval doesn't mean you've made it as a company. You still have to take the product to market. But getting approval is one of the key challenges of the medical devices market."
Tizhoosh says he's now in discussion with his investors to prepare to launch a technology he believes could "revolutionize" the oncology industry by providing easier, more reliable contours of tumours, a process that now takes an extraordinary amount of time for oncologists. "I am extremely happy, extremely proud, but we still have hard work ahead of us."
Tizhoosh says he expects to hire three or four new staff by January to help the company's growth, bringing his staff to 11 or 12 people.
Writer: Edward Keenan
Source: Dr. Hamid Tizhoosh, CEO, Segasist